Tandem AI

Tandem AI is an artificial intelligence drug discovery company that provides a proprietary web-based platform to accelerate pharmaceutical research and reduce drug development costs. The platform combines AI and machine learning with computational chemistry tools to streamline lead discovery, molecular optimization, and cheminformatics workflows for the global scientific community. Tandem AI’s technology enables researchers to run virtual screening, molecular dynamics simulations, and predictive modeling at scale, helping identify promising drug candidates faster than traditional methods. Founded in 2021 and headquartered in New York, the company has raised approximately $82 million in Series A funding. Investors include Orbimed, Eight Roads Ventures, F-Prime Capital, Qiming Venture Partners, Chengwei Capital, and V-Capital. With a team of approximately 52 employees, Tandem AI operates in the AI-based drug discovery and life sciences technology sector, targeting pharmaceutical companies, biotech firms, and academic research institutions seeking to improve R&D productivity.